Bascom discusses Penn State’s role in novel IPF trial on medical education platform
Rebecca Bascom, MD, MPH, professor of medicine and public health sciences, is featured in an interview on an online medical education platform about a clinical trial studying the efficacy of the drug tipelukast in patients suffering from idiopathic pulmonary fibrosis (IPF).
The educational platform, touchRESPIRATORY, is at “the forefront of on-demand and virtual formats, pushing the boundaries for online medical education,” according to its website. Bascom’s interview is showcased on the site’s Conference Hub, which houses highlights and coverage from leading international respiratory congresses.
In the video, Bascom discusses the challenges in treating IPF and recent evolutions in therapy, reviews what tipelukast is and how it works, and explores the aims and design of the first clinical trial of tipelukast.
This particular subject was important to share with a wider audience on touchRESPIRATORY, Bascom said, because it hits close to home for herself and her patients.
“Many of my patients suffer greatly from IPF. It is a rare and difficult disease with high morbidity and mortality,” Bascom said. “There is a continuing urgent need to develop new and improved therapies for IPF. The completion of this phase of testing a promising new therapy for IPF is a benchmark moment; Penn State was chosen by Medicinova to be the sole site for this phase of testing – and we want the greater community of people with IPF to have an update on our progress.”
If you're having trouble accessing this content, or would like it in another format, please email the Penn State College of Medicine web department.